About Eisai US
Eisai US news and updates
Epilepsy Foundation partnered with Eisai on May 3rd 21'.
LANDOVER, Md., Today the Epilepsy Foundation announced a collaboration with Eisai Inc. to develop a new platform — the Epilepsy Digital Experience Navigator (EDEN) — designed to empower people with epilepsy, their caregivers, and clinicians to use data to better understand and improve the epilepsy journey.
Jan 1, 2021 | epilepsy.comEisai recognized as White 500” company on Jan 1st 17'.
The program was launched in 2017, and this is the fourth time that Eisai was certified as a “White 500” company.
Jan 1, 2022 | eisai.comPharmafocusasia partners with Eisai
"Pharmafocusasia is very pleased to announce this important new partnership with Eisai, which brings together its complementary expertise and commitment in inflammation, to deliver this important new option to patients living with inflammatory diseases in Japan," said Luc Hermans, M.D., President and Representative Director, Gilead Japan.
Jan 1, 2019 | pharmafocusasia.comGeisinger Health partnered with Eisai on May 25th 22'.
Earlier this year Geisinger announced a partnership with Eisai to use an artificial intelligence algorithm to detect early signs of dementia.
Jan 1, 2022 | hitinfrastructure.comEisai acquires Arteryex
Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.
Jan 1, 2022 | informa.comEisai expands offices to Metro, Indonesia
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., has relocated its US headquarters to the ON3 Campus at 200 Metro Blvd. in Nutley.
Jan 1, 2022 | njbmagazine.comTokushima U partners with Eisai
About a year later, the University of Tokushima in Japan, in collaboration with Eisai, launched a Phase 3 trial called JETALS (NCT03548311) to confirm the results of the prior analyses.
Jan 1, 2022 | alsnewstoday.comEisai hires Fagan
Mr. Fagan joins Eisai with more than 20 years of experience serving the pharmaceutical, medical device and diagnostics industries during which time he accumulated roles of increasing responsibility across product and brand development, commercialization, business development and alliance management including seven years in roles dedicated to AD.
Jan 1, 2022 | yahoo.comEisai decreases headcount by 88
Eisai Co. shut down its oncology arm, H3 Pharmaceuticals, and laid off all 88 employees as part of a larger reorganization within the company.
Jan 1, 2022 | bisnow.comEisai launches Diancha
Buddhist priest "Eisai" introduced Diancha which he brought back from China, and then Japanese people developed their tea drinking ceremony by integrating their own aesthetic taste.
Jul 24, 2022 | taishanteaclub.com.auEisai launches Aricept in the U.S.
"Since Eisai launched Aricept in the U.S. and Japan in the late 1990s and obtained its approval in over 100 countries, Eisai has provided the drug to people living with dementia while building empathy for them and their families through disease education efforts and community involvement.
Sep 27, 2022 | jcnnewswire.comEisai launched Phase 3 confirmatory Clarity AD study on Sep 28th 22'.
BioArctic’s partner Eisai has announced results for the large global Phase 3 confirmatory Clarity AD study in 1,795 subjects.
Sep 28, 2022 | nordiclifescience.orgEisai launched data from lecanemab program in Alzheimer’s on May 10th 22'.
In September, Biogen’s developmental partner Eisai announced promising data from its lecanemab program in Alzheimer’s.
May 10, 2022 | biospace.comEisai launched Aricept on Jan 1st 97'.
In 1997, Eisai launched Aricept, a revolutionary treatment for the symptoms of Alzheimer’s disease, invented and developed by the company’s scientists in Japan.
Nov 17, 2022 | statnews.comEisai sells assets to DKSH (Shanghai) Ltd
DKSH has signed an agreement to acquire two pharma brands from Eisai for nine markets in Asia Pacific.
Nov 6, 2022 | dksh.comEisai launched encouraging topline data from the Clarity AD study on Nov 29th 22'.
The full phase three trial results were published Tuesday, roughly two months after Biogen and Eisai released encouraging topline data from the Clarity AD study.
Nov 30, 2022 | cnbc.comEisai expanded facilities to Nutley, New Jersey, United States on Jan 1st 20'.
Back in 2020, Eisai Inc. announced it would relocate its state-based headquarters to the ON3 campus in Nutley.
Dec 8, 2022 | njbiz.comEisai will expand facilities to Cambridge, Massachusetts, United States on Dec 11th 23'.
Japanese drug giant Eisai Inc. plans to open a new 80-employee center in Cambridge’s Alewife neighborhood next year devoted to developing drugs for Alzheimer’s disease, while closing a similar-sized site in Andover.
Dec 10, 2022 | thedaviscompanies.comEisai partners with UW Medicine
Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments.
Dec 15, 2022 | pharmaceutical-technology.com